24.26
price down icon0.86%   -0.21
pre-market  Vorhandelsmarkt:  24.35   0.09   +0.37%
loading
Schlusskurs vom Vortag:
$24.47
Offen:
$24.59
24-Stunden-Volumen:
33.39M
Relative Volume:
0.79
Marktkapitalisierung:
$137.93B
Einnahmen:
$62.46B
Nettoeinkommen (Verlust:
$7.88B
KGV:
17.58
EPS:
1.38
Netto-Cashflow:
$11.22B
1W Leistung:
-4.30%
1M Leistung:
+1.21%
6M Leistung:
-8.93%
1J Leistung:
-19.05%
1-Tages-Spanne:
Value
$24.25
$24.65
1-Wochen-Bereich:
Value
$24.25
$25.44
52-Wochen-Spanne:
Value
$20.91
$31.54

Pfizer Inc Stock (PFE) Company Profile

Name
Firmenname
Pfizer Inc
Name
Telefon
(212) 733-2323
Name
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Mitarbeiter
81,000
Name
Twitter
@Pfizer
Name
Nächster Verdiensttermin
2025-02-04
Name
Neueste SEC-Einreichungen
Name
PFE's Discussions on Twitter

Vergleichen Sie PFE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
PFE
Pfizer Inc
24.26 144.12B 62.46B 7.88B 11.22B 1.38
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.18 717.60B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.36 377.32B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.85 338.30B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.14 234.32B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.92 306.33B 43.59B 15.04B 10.74B 3.3766

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-22 Eingeleitet Cantor Fitzgerald Neutral
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-11-15 Eingeleitet Wolfe Research Underperform
2024-10-25 Fortgesetzt Citigroup Neutral
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-08-07 Hochstufung Daiwa Securities Neutral → Outperform
2024-03-22 Herabstufung Argus Buy → Hold
2024-02-23 Eingeleitet Guggenheim Buy
2024-01-04 Herabstufung TD Cowen Outperform → Market Perform
2023-10-20 Fortgesetzt UBS Neutral
2023-10-16 Hochstufung Jefferies Hold → Buy
2023-07-17 Bestätigt JP Morgan Neutral
2023-07-14 Eingeleitet HSBC Securities Buy
2023-06-29 Herabstufung Credit Suisse Outperform → Neutral
2023-05-11 Herabstufung Daiwa Securities Outperform → Neutral
2023-03-06 Eingeleitet Jefferies Hold
2023-02-07 Hochstufung Daiwa Securities Neutral → Outperform
2023-01-26 Herabstufung UBS Buy → Neutral
2023-01-17 Herabstufung Wells Fargo Overweight → Equal Weight
2023-01-04 Herabstufung BofA Securities Buy → Neutral
2022-12-13 Hochstufung Goldman Neutral → Buy
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-04-06 Fortgesetzt Morgan Stanley Equal-Weight
2022-01-05 Hochstufung BofA Securities Neutral → Buy
2022-01-03 Bestätigt Bernstein Mkt Perform
2021-12-20 Bestätigt Cowen Outperform
2021-12-17 Eingeleitet Goldman Neutral
2021-12-13 Hochstufung UBS Neutral → Buy
2021-12-09 Eingeleitet Wells Fargo Overweight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-07-27 Fortgesetzt Truist Buy
2021-05-06 Herabstufung Mizuho Buy → Neutral
2021-04-07 Fortgesetzt RBC Capital Mkts Sector Perform
2021-02-04 Hochstufung DZ Bank Hold → Buy
2020-12-16 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-11-19 Fortgesetzt Goldman Neutral
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-10-12 Herabstufung Atlantic Equities Overweight → Neutral
2020-09-29 Eingeleitet Berenberg Hold
2020-06-16 Eingeleitet SVB Leerink Mkt Perform
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-27 Hochstufung Standpoint Research Hold → Buy
2020-02-06 Eingeleitet Mizuho Buy
2020-01-07 Eingeleitet RBC Capital Mkts Outperform
2019-10-17 Fortgesetzt BofA/Merrill Neutral
2019-07-30 Herabstufung BofA/Merrill Buy → Neutral
2019-07-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2019-06-04 Fortgesetzt Morgan Stanley Overweight
2019-02-20 Fortgesetzt Citigroup Neutral
2019-01-31 Hochstufung Argus Hold → Buy
2019-01-31 Hochstufung Credit Suisse Neutral → Outperform
2019-01-23 Herabstufung UBS Buy → Neutral
2018-12-11 Herabstufung JP Morgan Overweight → Neutral
2018-11-01 Herabstufung BMO Capital Markets Outperform → Market Perform
Alle ansehen

Pfizer Inc Aktie (PFE) Neueste Nachrichten

pulisher
02:15 AM

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II - insights.citeline.com

02:15 AM
pulisher
12:51 PM

Request for Proposals: Pfizer Independent Medical Education Grant Program - fundsforNGOs

12:51 PM
pulisher
Jul 21, 2025

Lobbying Update: $3,490,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade - The Motley Fool

Jul 21, 2025
pulisher
Jul 20, 2025

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - AOL.com

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Pfizer Inc. stock priceFree Stock Market Return Analysis - Jammu Links News

Jul 20, 2025
pulisher
Jul 20, 2025

Pfizer Inc. Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Can Pfizer Limited (PFIZER) Maintain Its ValuationFree Market Volatility Navigation Tips - Jammu Links News

Jul 19, 2025
pulisher
Jul 19, 2025

Is Pfizer Inc. a good long term investmentOutstanding trading profits - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about Pfizer Inc. stockTremendous portfolio expansion - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Pfizer’s Discounted Stock Offers Yield, But Risks Linger - Finimize

Jul 19, 2025
pulisher
Jul 19, 2025

Sally Susman helped steer Pfizer through COVID-19. Her advice for leaders? Learn to write — and listen. - Business Insider

Jul 19, 2025
pulisher
Jul 18, 2025

Pfizer’s (PFE) Dividend Safety: Balancing Innovation and Shareholder Returns - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Maintains a Hold on Pfizer (PFE) - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Hemophilia Study: Insights into Treatment Patterns and Outcomes - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s BeneFIX Study Update: Key Insights for Investors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer in Maternal Health - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Lyme Disease Vaccine Study: Key Insights for Investors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Promising Phase 2 Study on Inotuzumab Ozogamicin for Pediatric Leukemia - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Rimegepant Study: A New Hope for Migraine Sufferers - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer in Infant RSV Prevention - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer's Global Health Fellows Program: Leveraging Colleagues’ Expertise to Help Improve Healthcare Access Around the World - Pfizer

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Latest Study on PF-07799544: A Potential Game-Changer for Advanced Solid Tumors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Rx Rundown: Sarep­ta Ther­a­peu­tics, Juul, Pfizer and more - Medical Marketing and Media

Jul 18, 2025
pulisher
Jul 18, 2025

BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum

Jul 18, 2025
pulisher
Jul 18, 2025

13 Cheap Stocks Under $50 to Buy Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Pfizer, Lilly spend big on telehealth contracts: Lawmaker report - Sherwood News

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit - insights.citeline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer Just Reversed Its Bull Run. Is It A Buy Or A Sell? - Investor's Business Daily

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program - simplywall.st

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s EPIC-Peds Study: A Potential Game-Changer for Pediatric COVID-19 Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s Phase 1 Study on PF-07941944: Key Insights for Investors - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s Pediatric Leukemia Study: Implications for BESPONSA’s Market Potential - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to offer Eliquis at a discount for some patients - BioPharma Dive

Jul 17, 2025
pulisher
Jul 17, 2025

Major drugmakers offer big discount on blood thinner Eliquis - Fox Business

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb (BMY) and Pfizer (PFE) Stocks Jump on Eliquis Drug Discount - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Lifestyle Drugs Market Future Business Opportunities - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg

Jul 17, 2025
pulisher
Jul 17, 2025

BMS-Pfizer alliance to offer Eliquis at 40% discount to cash-paying patients - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan

Jul 17, 2025
pulisher
Jul 17, 2025

Exclusive | Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount - The Wall Street Journal

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours - Stocktwits

Jul 17, 2025

Finanzdaten der Pfizer Inc-Aktie (PFE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$108.28
price up icon 0.06%
drug_manufacturers_general SNY
$47.93
price down icon 0.81%
$295.87
price up icon 0.38%
drug_manufacturers_general MRK
$79.31
price down icon 0.81%
drug_manufacturers_general NVO
$64.92
price up icon 0.95%
Kapitalisierung:     |  Volumen (24h):